Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat
by Zacks Equity Research
Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.
Pharma ETFs Down Post Q3 Earnings
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
by Arpita Dutt
It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.
Dow 30 Stock Roundup: Chevron, Exxon, Apple Earnings Impress
by Swarup Gupta
The Dow continued to notch up gains during a week marked by key legislative developments.
Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.
Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
by Zacks Equity Research
Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.
AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.
Company News For Nov 1, 2017
by Zacks Equity Research
Companies in the news are: PFE, UA,AET, ACOR
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.
Stocks To Watch Out For This Halloween
by Zacks Equity Research
Stocks To Watch Out For This Halloween
Will Markets Stay Spooked This Halloween?
by Mark Vickery
While econ data looks favorable, ahead of the opening bell we also see plenty of strength in Q3 performance.
Pfizer (PFE) Tops Q3 Earnings Estimates, Sales In Line
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised adjusted earnings guidance while tightening the revenue expectations for 2017.
Is Aerie (AERI) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers
by Arpita Dutt
It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).
Merck vs. Pfizer: Which is Better Ahead of Q3 Earnings?
by Swarup Gupta
With Merck and Pfizer scheduled to report on Oct 27 and Oct 31, respectively this may be a good time to consider which of these is a better stock.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.
Corning (GLW) Beats Q3 Earnings on High Gorilla Glass Demand
by Zacks Equity Research
Corning's (GLW) third-quarter results benefited from the revenue upside driven by strong sales of Gorilla Glass and fiber products.
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Healthcare ETFs Set to Soar as Q3 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, healthcare ETFs are set to soar.